Savara, Inc. (SVRA) analyst actions
Rating and price-target actions on SVRA in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the SVRA overview →
2 measured SVRA analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Savara Inc. (SVRA) And Encourages Shareholders to Reach Out | Press release | -0.15% | -0.23% | |
| Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | Press release | +1.29% | +4.53% |
Keep exploring
More SVRA: earnings → · SEC filings → · SVRA overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| GraniteShares YieldBOOST CRCL ETF (CRY) | 1,038 | 0.00% | 49% |
| Canopy Growth Corporation - Common Shares (CGC) | 1,033 | -0.77% | 37% |
| INTREXON CORP (XON) | 1,025 | +0.05% | 52% |
| Ardelyx, Inc. (ARDX) | 1,024 | -0.09% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.